A paradigm shift in rheumatoid arthritis over the past decade

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Recent advances have improved our understanding of the pathogenesis of rheumatoid arthritis (RA), and the development of new therapeutics, including biological agents, have thus made it possible to strive for remission as a primary goal. Biological agents targeting a specific molecule have powerful functional capabilities, and the introduction of biological therapies has brought about revolutionary progress in RA management, culminating in a paradigm shift. There is clear evidence that a delay in treatment initiation and poor control of disease activity are associated with joint damage progression, so treatment should be started immediately after the diagnosis of RA and adapted according to disease activity as assessed by validated composite measures. In this review, we will summarize the changes in the classification and remission criteria and describe the clinical efficacies of biological agents in RA. We also discuss new promising therapies and propose future perspectives in the rheumatology field.

Original languageEnglish
Pages (from-to)1895-1903
Number of pages9
JournalInternal Medicine
Volume53
Issue number17
DOIs
Publication statusPublished - 2014

Fingerprint

Rheumatoid Arthritis
Biological Factors
Biological Therapy
Rheumatology
Therapeutics
Joints

Keywords

  • Biological agent
  • Paradigm shift
  • Rheumatoid arthritis
  • Treat-to-target

ASJC Scopus subject areas

  • Internal Medicine

Cite this

A paradigm shift in rheumatoid arthritis over the past decade. / Kaneko, Yuko; Takeuchi, Tsutomu.

In: Internal Medicine, Vol. 53, No. 17, 2014, p. 1895-1903.

Research output: Contribution to journalArticle

@article{2c3d03b6586a4347b0eaf39f4389d11b,
title = "A paradigm shift in rheumatoid arthritis over the past decade",
abstract = "Recent advances have improved our understanding of the pathogenesis of rheumatoid arthritis (RA), and the development of new therapeutics, including biological agents, have thus made it possible to strive for remission as a primary goal. Biological agents targeting a specific molecule have powerful functional capabilities, and the introduction of biological therapies has brought about revolutionary progress in RA management, culminating in a paradigm shift. There is clear evidence that a delay in treatment initiation and poor control of disease activity are associated with joint damage progression, so treatment should be started immediately after the diagnosis of RA and adapted according to disease activity as assessed by validated composite measures. In this review, we will summarize the changes in the classification and remission criteria and describe the clinical efficacies of biological agents in RA. We also discuss new promising therapies and propose future perspectives in the rheumatology field.",
keywords = "Biological agent, Paradigm shift, Rheumatoid arthritis, Treat-to-target",
author = "Yuko Kaneko and Tsutomu Takeuchi",
year = "2014",
doi = "10.2169/internalmedicine.53.2834",
language = "English",
volume = "53",
pages = "1895--1903",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "17",

}

TY - JOUR

T1 - A paradigm shift in rheumatoid arthritis over the past decade

AU - Kaneko, Yuko

AU - Takeuchi, Tsutomu

PY - 2014

Y1 - 2014

N2 - Recent advances have improved our understanding of the pathogenesis of rheumatoid arthritis (RA), and the development of new therapeutics, including biological agents, have thus made it possible to strive for remission as a primary goal. Biological agents targeting a specific molecule have powerful functional capabilities, and the introduction of biological therapies has brought about revolutionary progress in RA management, culminating in a paradigm shift. There is clear evidence that a delay in treatment initiation and poor control of disease activity are associated with joint damage progression, so treatment should be started immediately after the diagnosis of RA and adapted according to disease activity as assessed by validated composite measures. In this review, we will summarize the changes in the classification and remission criteria and describe the clinical efficacies of biological agents in RA. We also discuss new promising therapies and propose future perspectives in the rheumatology field.

AB - Recent advances have improved our understanding of the pathogenesis of rheumatoid arthritis (RA), and the development of new therapeutics, including biological agents, have thus made it possible to strive for remission as a primary goal. Biological agents targeting a specific molecule have powerful functional capabilities, and the introduction of biological therapies has brought about revolutionary progress in RA management, culminating in a paradigm shift. There is clear evidence that a delay in treatment initiation and poor control of disease activity are associated with joint damage progression, so treatment should be started immediately after the diagnosis of RA and adapted according to disease activity as assessed by validated composite measures. In this review, we will summarize the changes in the classification and remission criteria and describe the clinical efficacies of biological agents in RA. We also discuss new promising therapies and propose future perspectives in the rheumatology field.

KW - Biological agent

KW - Paradigm shift

KW - Rheumatoid arthritis

KW - Treat-to-target

UR - http://www.scopus.com/inward/record.url?scp=84906823422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906823422&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.53.2834

DO - 10.2169/internalmedicine.53.2834

M3 - Article

C2 - 25175120

AN - SCOPUS:84906823422

VL - 53

SP - 1895

EP - 1903

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 17

ER -